Integrated Filing — IndAS



General information about company

Scrip Code 506414
NSE Symbol FERMENTA
MSEI Symbol NOTLISTED
ISIN INE225B01021
Name of company FERMENTA BIOTECH LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 05-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 29-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 05-11-2026   12:00:00
End date and time of board meeting 05-11-2026   12:39:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 09-02-2026
Indicate Company website link for updated RPT policy of the Company https://fermentabiotech.com/policies/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Disclosure for the default on loans and debt securities is not applicable to the entity.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 11,693.63 22,877.56
Other income 364.92 854.58
Total income 12,058.55 23,732.14
2 Expenses
(a) Cost of materials consumed 3,162.12 7,647.88
(b) Purchases of stock-in-trade 152.47 282.66
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 724.90 (337.66)
(d) Employee benefit expense 2,080.26 4,085.41
(e) Finance costs 373.30 627.21
(f) Depreciation, depletion and amortisation expense 519.83 1,038.44
(f) Other Expenses
1 Other expenses 3,169.10 6,497.05
Total other expenses 3,169.10 6,497.05
Total expenses 10,181.98 19,840.99
3 Total profit before exceptional items and tax 1,876.57 3,891.15
4 Exceptional items 0.00 0.00
5 Total profit before tax 1,876.57 3,891.15
6 Tax expense
7 Current tax 454.79 890.88
8 Deferred tax 26.42 106.33
9 Total tax expenses 481.21 997.21
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 1,395.36 2,893.94
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 1,395.36 2,893.94
17 Other comprehensive income net of taxes 1.78 1.27
18 Total Comprehensive Income for the period 1,397.14 2,895.21
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,436.37 1,436.37
Face value of equity share capital 5 5
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 4.86 10.09
Diluted earnings (loss) per share from continuing operations 4.77 9.9
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 4.86 10.09
Diluted earnings (loss) per share from continuing and discontinued operations 4.77 9.9
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 2. The above unaudited standalone financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 05th November, 2026. The results of the Company are available for investors at www.fermentabiotech.com, www.bseindia.com and www.nseindia.com in accordance with the provision of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 3 These unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) (’Ind AS’) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 4 During the previous year, the company sold a portion of its investment property comprising freehold land situated at Village Takawe. The gain arising from such sale amounted to Rs.Nil lakhs for the quarter ended September 30, 2026, the half year ended September 30, 2026 and for the quarter ended June 30, 2026 (quarter ended September 30, 2025: Rs. Nil lakhs; half year ended September 30, 2025: Rs. 162.89 lakhs and for the year ended March 31, 2026 amounted to Rs. 162.89 lakhs). The said income has been recognized under 'Revenue from Operations' pertaining to the Property Segment. 5 During the previous year, the company transferred its Environment Division to its wholly owned subsidiary, Fermenta Environment Solutions Private Limited, as a going concern on a slump sale basis with effect from October 01,2025, for a consideration of Rs. 1,900 lakhs. 6 During the current period, the company has consumed semi-finished inventory provided for in the earlier year towards the production of animal feed and accordingly such provision has been reversed for the quarter ended September 30, 2026 Rs. Nil lakhs, for the quarter ended June 30, 2026 and for the half year ended September 30, 2026 ended is Rs. 205.00 lakhs (quarter ended September 30, 2025 and for the half year ended September 30, 2025: Rs. 505.55 lakhs and for the year ended March 31, 2026 is Rs. 1,023.73 lakhs). 7 In the earlier years, the company had recognised provision against certain receivables and trade receivables. The company recovered part amount of Rs. 907.14 lakhs against these provided balances and accordingly such provision was reversed and recorded as an exceptional items in the year ended March 31, 2026. 8 During the previous year, the company assessed the potential impact of increased employee benefit obligations arising from the implementation of the Labour Codes, based on its best estimate and in consultation with external experts. Accordingly, the Company recognised a provision of Rs. 210.52 lakhs for the year ended March 31, 2026 in accordance with Ind AS 19, Employee Benefits, which was disclosed as exceptional item. 9 Figures of the previous periods have been regrouped/ reclassified wherever necessary to conform to the current period classification.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 20,261.55
Capital work-in-progress 2,273.94
Investment property 303.60
Goodwill 411.65
Other intangible assets 229.66
Intangible assets under development 10.74
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 43.65
Trade receivables, non-current 0.00
Loans, non-current 2,675.53
Other non-current financial assets
1 Other financial assets 605.78
2 Right of use assets 429.33
3 Investments in subsidiaries 1,120.06
Total of other non-current financial assets 2,155.17
Total non-current financial assets 4,874.35
Deferred tax assets (net) 1,729.58
Other non-current assets
1 Non-current tax assets 19.99
2 Other non-current assets 305.73
Total of other non-current assets 325.72
Total non-current assets 30,420.79
2 Current assets
Inventories 13,905.32
Current financial asset
Current investments 0.00
Trade receivables, current 16,082.14
Cash and cash equivalents 1,065.16
Bank balance other than cash and cash equivalents 2,892.62
Loans, current 2.50
Other current financial assets
Total of other current financial assets 4,723.40
Total current financial assets 24,765.82
Current tax assets (net) 0.00
Other current assets
1 Other current assets 1,845.29
Total of other current assets 1,845.29
Total current assets 40,516.43
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 70,937.22
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,436.37
Other equity 42,982.50
Total equity attributable to owners of parent 44,418.87
Non controlling interest
Total equity 44,418.87
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 324.65
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Other financial liabilities 1,673.24
2 Lease liabilities 249.28
Total of other non-current financial liabilities 1,922.52
Total non-current financial liabilities 2,247.17
Provisions, non-current 1,012.00
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other non-current liabilities 4.53
Total of other non-current liabilities 4.53
Total non-current liabilities 3,263.70
Current liabilities
Current financial liabilities
Borrowings, current 10,149.13
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 800.50
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 7,115.90
Total Trade payable 7,916.40
Other current financial liabilities
1 Other financial liabilities 646.77
2 Lease liabilities 135.09
Total of other current financial liabilities 781.86
Total current financial liabilities 18,847.39
Other current liabilities 3,718.48
1 Other current liabilities 3,718.48
Total of other current liabilities 3,718.48
Provisions, current 97.58
Current tax liabilities (Net) 591.20
Deferred government grants, Current 0.00
Total current liabilities 23,254.65
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 26,518.35
Total equity and liabilites 70,937.22
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Bulk drugs/chemicals 11,733.80 23,075.76
2 Property 0.0019838 0.0039774
3 Unallocated 0.0012637 0.0025864
Total Segment Revenue 12,058.55 23,732.14
Less: Inter segment revenue 0.00 0.00
Revenue from operations 12,058.55 23,732.14
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Bulk drugs/chemicals 2,122.33 4,251.71
2 Property 1.17 8.01
3 Unallocated 126.37 258.64
Total Profit before tax 2,249.87 4,518.36
i. Finance cost 373.30 627.21
ii. Other Unallocable Expenditure net off Unallocable income 0.00 0.00
Profit before tax 1,876.57 3,891.15
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Bulk drugs/chemicals 56,636.70 56,636.70
2 Property 1,118.73 1,118.73
3 Unallocated 13,181.80 13,181.80
Total Segment Asset 70,937.23 70,937.23
Un-allocable Assets 0.00 0.00
Net Segment Asset 70,937.23 70,937.23
4 Segment Liabilities
Segment Liabilities
1 Bulk drugs/chemicals 10,185.43 10,185.43
2 Property 5,196.81 5,196.81
3 Unallocated 11,136.12 11,136.12
Total Segment Liabilities 26,518.36 26,518.36
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 26,518.36 26,518.36
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
1 Net fair value change in investment in equity instruments through other 2.38 1.70
Total Amount of items that will be reclassified to profit and loss 2.38 1.70
4 Income tax relating to items that will be reclassified to profit or loss 0.60 0.43
5 Total Other comprehensive income 1.78 1.27



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 3,891.15
Adjustments for reconcile profit (loss)
Adjustments for finance costs 627.21
Adjustments for decrease (increase) in inventories (634.76)
Adjustments for decrease (increase) in trade receivables, current (1,657.45)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 43.45
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 1,914.92
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 2,003.21
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 1,038.44
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (7.08)
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (140.60)
Adjustments for dividend income 0.44
Adjustments for interest income 296.62
Adjustments for share-based payments 270.20
Adjustments for fair value losses (gains) (38.81)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (379.53)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 2,742.14
Net cash flows from (used in) operations 6,633.29
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 403.70
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 6,229.59
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 3.35
Purchase of property, plant and equipment 1,730.16
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 1.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.44
Interest received 75.28
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (1,530.00)
Net cash flows from (used in) investing activities (3,180.09)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 47.41
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 1,265.38
Payments of lease liabilities 76.57
Dividends paid 1,075.52
Interest paid 634.55
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (3,004.61)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 44.89
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 44.89
Cash and cash equivalents cash flow statement at beginning of period (863.82)
Cash and cash equivalents cash flow statement at end of period (818.93)





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 S R B C CO LLP Yes 28-02-2029


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Fermenta Biotech Limited Krishna Datla Key Management Personnel Remuneration Approved 184.33 0.00 0.00
2 Fermenta Biotech Limited Satish Varma Key Management Personnel Remuneration Approved 151.59 0.00 0.00
3 Fermenta Biotech Limited Anupama Datla Desai Key Management Personnel Remuneration Approved 109.31 0.00 0.00
4 Fermenta Biotech Limited Prashant Nagre Key Management Personnel Remuneration Approved 184.76 0.00 0.00
5 Fermenta Biotech Limited Sumesh Gandhi Key Management Personnel Remuneration Approved 97.67 0.00 0.00
6 Fermenta Biotech Limited Varadvinayak Khambete Key Management Personnel Remuneration Approved 19.68 0.00 0.00
7 Fermenta Biotech Limited Rajeshwari Datla Key Management Personnel Any other transaction Sitting Fees Approved 3.20 0.00 0.00
8 Fermenta Biotech Limited Rajashri Ojha Key Management Personnel Any other transaction Sitting Fees Approved 4.70 0.00 0.00
9 Fermenta Biotech Limited Pramod Kasat Key Management Personnel Any other transaction Sitting Fees Approved 5.80 0.00 0.00
10 Fermenta Biotech Limited Ramanand Mundkur Key Management Personnel Any other transaction Sitting Fees Approved 5.60 0.00 0.00
11 Fermenta Biotech Limited PRADEEP MANJUNATH CHANDAN Key Management Personnel Any other transaction Sitting Fees Approved 3.20 0.00 0.00
12 Fermenta Biotech Limited M/s Kamml Technologies Enterprises under significant influence of key management personnel or their relatives Sale of goods or services Approved 20.22 0.00 0.00
13 Fermenta Biotech Limited M/s Kamml Technologies Enterprises under significant influence of key management personnel or their relatives Any other transaction Trade receivables and reimbursement receivables Approved 0.00 3.31 7.88
14 Fermenta Biotech Limited Health and Wellness India Private Limited Associate Any other transaction Allowance for doubtful debts/advances Approved 0.00 37.00 37.00
15 Fermenta Biotech Limited Health and Wellness India Private Limited Associate Any other transaction Provision for diminution in value of investments Approved 0.00 784.86 784.86
16 Fermenta Biotech Limited Health and Wellness India Private Limited Associate Inter-corporate deposit Approved 0.00 37.00 37.00
17 Fermenta Biotech Limited Fermenta Biotech GMBH Subsidiary Sale of goods or services Approved 1,200.21 0.00 0.00
18 Fermenta Biotech Limited Fermenta USA LLC Subsidiary Sale of goods or services Approved 577.37 0.00 0.00
19 Fermenta Biotech Limited Fermenta Biotech Gmbh Subsidiary Any other transaction Services Availed Approved 270.84 0.00 0.00
20 Fermenta Biotech Limited Fermenta Biotech Gmbh Subsidiary Any other transaction Payable for services Approved 0.00 0.00 270.84
21 Fermenta Biotech Limited Fermenta Biotech USA LLC Subsidiary Any other transaction Interest on loan given Approved 20.27 0.00 0.00
22 Fermenta Biotech Limited Fermenta Biotech Gmbh Subsidiary Any other transaction Trade receivables and reimbursement receivables Approved 0.00 5,448.43 6,192.79
23 Fermenta Biotech Limited Fermenta USA LLC Subsidiary Any other transaction Trade receivables and reimbursement receivables Approved 0.00 1,506.70 1,645.50
24 Fermenta Biotech Limited Fermenta Biotech USA LLC Subsidiary Any other transaction Interest on loan given receivables Approved 0.00 9.94 30.46
25 Fermenta Biotech Limited Fermenta Biotech Gmbh Subsidiary Any other transaction Provision for diminution in value of investments Approved 0.00 831.21 831.21
26 Fermenta Biotech Limited Fermenta Biotech Gmbh Subsidiary Any other transaction Provision for doubtful trade receivable and expenditure incurred on behalf. Approved 0.00 2,780.03 2,780.03
27 Fermenta Biotech Limited Fermenta Biotech USA LLC Subsidiary Any other transaction Provision for diminution in value of investments Approved 0.00 900.00 900.00
28 Fermenta Biotech Limited Fermenta Biotech (UK) Limited Subsidiary Any other transaction Provision for diminution in value of investments Approved 0.00 148.65 148.65
29 Fermenta Biotech Limited Fermenta Biotech USA LLC Subsidiary Any other transaction Loan given Approved 0.00 806.08 814.53
30 Fermenta Biotech Limited Fermenta Environment Solutions Private Limited Subsidiary Any other transaction Rent Income Approved 6.03 0.00 0.00
31 Fermenta Biotech Limited Fermenta Environment Solutions Private Limited Subsidiary Any other transaction Invoice towards Support Services Approved 30.00 0.00 0.00
32 Fermenta Biotech Limited Fermenta Environment Solutions Private Limited Subsidiary Any other transaction Interest on Loan given Approved 72.02 0.00 0.00
33 Fermenta Biotech Limited Fermenta Environment Solutions Private Limited Subsidiary Any other transaction Trade payable Approved 0.00 240.68 203.31
34 Fermenta Biotech Limited Fermenta Environment Solutions Private Limited Subsidiary Any other transaction Trade receivables and reimbursement receivables Approved 0.00 72.00 100.19
35 Fermenta Biotech Limited Fermenta Environment Solutions Private Limited Subsidiary Any other transaction Interest on loan given receivables Approved 0.00 0.00 72.02
36 Fermenta Biotech Limited Fermenta Environment Solutions Private Limited Subsidiary Any other transaction Loan given Approved 0.00 1,400.00 1,750.00
Total value of transaction during the reporting period 2,966.80